Table IV.

Drug of target lactate in liver diseases.

Drug	Target	Function	(Refs.)
Curcumol	KLF5/LDHA	Attenuates liver fibrosis	(145)
2-DG	HK2	Improves liver fibrosis, and increases the antitumor effects of anti-PD-1 and sorafenib, while showing antitumor effects in anti-PD-1-resistant tumors	(147-152)
3-BrPA	HK2	Inhibits HCC cell proliferation and motility, and improves the efficacy of sorafenib in HCC models	(153-155)
Quercetin	HK2	Inhibits the proliferation HCC cells	(156)
ORPH	Glycolysis	Inhibits the growth and metastasis of HCC	(157)
Galloflavin	LDHA	Attenuates liver injury in the mouse model of ALF, and inhibits the proliferation of HCC cells	(158,159)
Quinoline-3-sulfonamides	LDHA	Inhibits the proliferation of HCC cells	(159)
Oxamate	LDHA	Enhances the antitumor activity of sorafenib, imatinib and sunitinib against HCC cells	(160)
VB124	MCT4	Enhances T cell infiltration and the efficacy of anti-PD-1 immunotherapy in a HCC mouse model	(164)
Demethylzeylasteral	Lactylation	Inhibits the development of HCC	(57)
RJA	Lactylation	Inhibits the proliferation and migration of HCC cells	(165)

2-DG, 2-deoxy-D-glucose; KLF5, Kruppel like factor 5; LDH, lactate dehydrogenase; HK2, hexokinase 2; PD-1, programmed death-1; 3-BrPA, 3-bromopyruvate; HCC, hepatocellular carcinoma; ORPH, oviductus ranae protein hydrolysate; ALF, acute liver failure; MCT, monocarboxylate transporter; RJA, royal jelly acid.